Literature DB >> 31620221

Lysophosphatidic Acid Receptor 1 Antagonists for the Treatment of Fibrosis.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2019        PMID： 31620221      PMCID： PMC6792147          DOI： 10.1021/acsmedchemlett.9b00429

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.

Authors:  David C Budd; Yimin Qian
Journal:  Future Med Chem       Date:  2013-10       Impact factor: 3.808

Review 2.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

Review 3.  Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis.

Authors:  Fang Yang; Guo-Xun Chen
Journal:  World J Gastroenterol       Date:  2018-09-28       Impact factor: 5.742
  3 in total
  1 in total

Review 1.  Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis.

Authors:  Souvik Banerjee; Suechin Lee; Derek D Norman; Gabor J Tigyi
Journal:  Molecules       Date:  2022-08-26       Impact factor: 4.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.